Skip to main content
Grant Details

Grant Number: 5R01CA220002-05 Interpret this number
Primary Investigator: Burridge, Paul
Organization: Northwestern University At Chicago
Project Title: Genomic Prediction of Doxorubicin-Induced Cardiotoxicity
Fiscal Year: 2022


Project Summary The anthracycline doxorubicin used in approximately 60% of pediatric cancer patients with metastatic solid tumors (sarcomas), blastomas, leukemia, and lymphoma. Treatments using doxorubicin are complicated by its well-established cardiotoxic side effect, which affects approximately 16% of pediatric patients, can lead to heart failure requiring heart transplant, and limits doxorubicin’s clinical utilization. Despite more than 50 years of research in this field, there is still, at present, little potential for either predicting or preventing cardiotoxicity. There is an obvious need for novel and innovative approaches to overcome this hurdle. Candidate gene association studies and genome–wide association studies (GWAS) have identified many single nucleotide polymorphisms (SNPs) that are statistically correlated with doxorubicin–induced cardiotoxicity (DIC), yet experimental validation of these SNPs has not been feasible due to the difficulty in isolating and culturing human cardiomyocytes in vitro. In our recent work, we showed that patient–specific human induced pluripotent stem cell–derived cardiomyocytes (hiPSC–CM) are efficient predictors of a patient’s likelihood of developing DIC, confirming for the first time that there is a genomic basis to DIC. Although GWAS has proven to be a powerful methodology for informing such genomic bases, it detects correlation rather than causation, and identified SNPs commonly fail to be replicated in subsequent studies. Here, we hypothesize that hiPSC-CMs can be utilized in three different modalities to study genetic variants associated with DIC: firstly, to discover novel predictive SNPs; secondly, to validate SNPs; and thirdly, to examine the modulated pathways and determine genotype-specific cardioprotective methodologies. In Aim 1, we will recruit 100 pediatric cancer patients who were exposed to doxorubicin and assess the response of patient-derived hiPSC-CM to doxorubicin in vitro to validate our previous findings in a large pediatric cohort with diverse biological covariates to verify the power of this tool. In Aim 2, we will use these 100 patient-specific lines to identify drug response differential expression quantitative trait loci (deQTL), assessing biological covariates such as dose, age, sex, SF, and cancer diagnosis both individually and combined. We will then validate these variants with genome editing, and mechanistically examine pathways causative to DIC susceptibility concentrating on genes with known roles in cardiomyopathy, cardioprotection, and doxorubicin metabolism. In Aim 3, we will interrogate the rigor and reproducibility of >40 existing DIC SNP studies, using CRISPR/Cas9 to edit the gene of interest in control isogenic hiPSC lines then assess the response of hiPSC-CM to doxorubicin. We will then use the discoveries above to discover/repurpose genome-informed cardioprotective drugs to prevent DIC in a genotype-specific manner. In summary, this work will deliver us the genetic rationale for why patients experience DIC and provide 1, fully human validated SNP data for clinical application, and 2, novel cardioprotective drugs to attenuate DIC.


A Novel Locus on 6p21.2 for Cancer Treatment-Induced Cardiac Dysfunction Among Childhood Cancer Survivors.
Authors: Sapkota Y. , Ehrhardt M.J. , Qin N. , Wang Z. , Liu Q. , Qiu W. , Shelton K. , Shao Y. , Plyler E. , Mulder H.L. , et al. .
Source: Journal of the National Cancer Institute, 2022-08-08; 114(8), p. 1109-1116.
PMID: 35698272
Related Citations

Prime time for doxorubicin-induced cardiotoxicity genetic testing.
Authors: Magdy T. , Burridge P.W. .
Source: Pharmacogenomics, 2022 Apr; 23(6), p. 335-338.
EPub date: 2022-04-05.
PMID: 35380470
Related Citations

Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.
Authors: Magdy T. , Jouni M. , Kuo H.H. , Weddle C.J. , Lyra-Leite D. , Fonoudi H. , Romero-Tejeda M. , Gharib M. , Javed H. , Fajardo G. , et al. .
Source: Circulation, 2022-01-25; 145(4), p. 279-294.
EPub date: 2021-12-07.
PMID: 34874743
Related Citations

RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.
Authors: Magdy T. , Jiang Z. , Jouni M. , Fonoudi H. , Lyra-Leite D. , Jung G. , Romero-Tejeda M. , Kuo H.H. , Fetterman K.A. , Gharib M. , et al. .
Source: Cell stem cell, 2021-12-02; 28(12), p. 2076-2089.e7.
EPub date: 2021-09-15.
PMID: 34525346
Related Citations

Cellular model systems to study cardiovascular injury from chemotherapy.
Authors: Fonoudi H. , Burridge P.W. .
Source: Journal of thrombosis and thrombolysis, 2021 May; 51(4), p. 890-896.
EPub date: 2020-10-13.
PMID: 33051807
Related Citations

An updated protocol for the cost-effective and weekend-free culture of human induced pluripotent stem cells.
Authors: Lyra-Leite D.M. , Fonoudi H. , Gharib M. , Burridge P.W. .
Source: STAR protocols, 2021-03-19; 2(1), p. 100213.
EPub date: 2021-02-03.
PMID: 33786455
Related Citations

Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.
Authors: Magdy T. , Burridge P.W. .
Source: Pharmacogenomics, 2021 Jan; 22(1), p. 41-54.
EPub date: 2021-01-15.
PMID: 33448871
Related Citations

Tragacanth Gum/Chitosan Polyelectrolyte Complexes-Based Hydrogels Enriched with Xanthan Gum as Promising Materials for Buccal Application.
Authors: Potaś J. , Szymańska E. , Basa A. , Hafner A. , Winnicka K. .
Source: Materials (Basel, Switzerland), 2020-12-27; 14(1), .
EPub date: 2020-12-27.
PMID: 33375434
Related Citations

Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer-A Children's Oncology Group ALTE03N1 report.
Authors: Singh P. , Wang X. , Hageman L. , Chen Y. , Magdy T. , Landier W. , Ginsberg J.P. , Neglia J.P. , Sklar C.A. , Castellino S.M. , et al. .
Source: Cancer, 2020-09-01; 126(17), p. 4051-4058.
EPub date: 2020-05-15.
PMID: 32413235
Related Citations

Generating a Cost-Effective, Weekend-Free Chemically Defined Human Induced Pluripotent Stem Cell (hiPSC) Culture Medium.
Authors: Fonoudi H. , Lyra-Leite D.M. , Javed H.A. , Burridge P.W. .
Source: Current protocols in stem cell biology, 2020 Jun; 53(1), p. e110.
PMID: 32463953
Related Citations

Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity.
Authors: Pinheiro E.A. , Magdy T. , Burridge P.W. .
Source: Journal of cardiovascular translational research, 2020 Jun; 13(3), p. 377-389.
EPub date: 2020-02-20.
PMID: 32078739
Related Citations

Precise and Cost-Effective Nanopore Sequencing for Post-GWAS Fine-Mapping and Causal Variant Identification.
Authors: Magdy T. , Kuo H.H. , Burridge P.W. .
Source: iScience, 2020-04-24; 23(4), p. 100971.
EPub date: 2020-03-09.
PMID: 32203907
Related Citations

Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.
Authors: Gintant G. , Burridge P. , Gepstein L. , Harding S. , Herron T. , Hong C. , Jalife J. , Wu J.C. .
Source: Circulation research, 2019-10-25; 125(10), p. e75-e92.
EPub date: 2019-09-19.
PMID: 31533542
Related Citations

hiPSCs in cardio-oncology: deciphering the genomics.
Authors: Pinheiro E.A. , Fetterman K.A. , Burridge P.W. .
Source: Cardiovascular research, 2019-04-15; 115(5), p. 935-948.
PMID: 30689737
Related Citations

Late onset heart failure after childhood chemotherapy.
Authors: Hilfiker-Kleiner D. , Ardehali H. , Fischmeister R. , Burridge P. , Hirsch E. , Lyon A.R. .
Source: European heart journal, 2019-03-07; 40(10), p. 798-800.
PMID: 30753420
Related Citations

Are These Cardiomyocytes? Protocol Development Reveals Impact of Sample Preparation on the Accuracy of Identifying Cardiomyocytes by Flow Cytometry.
Authors: Waas M. , Weerasekera R. , Kropp E.M. , Romero-Tejeda M. , Poon E.N. , Boheler K.R. , Burridge P.W. , Gundry R.L. .
Source: Stem cell reports, 2019-02-12; 12(2), p. 395-410.
EPub date: 2019-01-24.
PMID: 30686762
Related Citations

Unraveling Difficult Answers: From Genotype to Phenotype in Coronary Artery Disease.
Authors: Magdy T. , Burridge P.W. .
Source: Cell stem cell, 2019-02-07; 24(2), p. 203-205.
PMID: 30735646
Related Citations

Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
Authors: Magdy T. , Schuldt A.J.T. , Wu J.C. , Bernstein D. , Burridge P.W. .
Source: Annual review of pharmacology and toxicology, 2018-01-06; 58, p. 83-103.
EPub date: 2017-10-06.
PMID: 28992430
Related Citations

The future role of pharmacogenomics in anticancer agent-induced cardiovascular toxicity.
Authors: Magdy T. , Burridge P.W. .
Source: Pharmacogenomics, 2018 Jan; 19(2), p. 79-82.
EPub date: 2017-12-04.
PMID: 29199515
Related Citations

Back to Top